Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1991 2
1992 7
1993 13
1994 12
1995 13
1996 15
1997 15
1998 28
1999 28
2000 33
2001 31
2002 40
2003 45
2004 56
2005 73
2006 60
2007 67
2008 81
2009 74
2010 85
2011 85
2012 84
2013 78
2014 79
2015 87
2016 70
2017 81
2018 80
2019 89
2020 78
2021 85
2022 81
2023 84
2024 45

Text availability

Article attribute

Article type

Publication date

Search Results

1,709 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer.
Chae CS, Sandoval TA, Hwang SM, Park ES, Giovanelli P, Awasthi D, Salvagno C, Emmanuelli A, Tan C, Chaudhary V, Casado J, Kossenkov AV, Song M, Barrat FJ, Holcomb K, Romero-Sandoval EA, Zamarin D, Pépin D, D'Andrea AD, Färkkilä A, Cubillos-Ruiz JR. Chae CS, et al. Cancer Discov. 2022 Aug 5;12(8):1904-1921. doi: 10.1158/2159-8290.CD-21-1181. Cancer Discov. 2022. PMID: 35552618 Free PMC article.
Lysophosphatidic acid (LPA) is a bioactive lipid enriched in the tumor microenvironment of immunosuppressive malignancies such as ovarian cancer. Although LPA enhances the tumorigenic attributes of cancer cells, the immunomodulatory activity of this ph …
Lysophosphatidic acid (LPA) is a bioactive lipid enriched in the tumor microenvironment of immunosuppressive malignancies such …
Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials.
Lin YH, Lin YC, Chen CC. Lin YH, et al. Cells. 2021 Jun 29;10(7):1629. doi: 10.3390/cells10071629. Cells. 2021. PMID: 34209775 Free PMC article. Review.
Lysophosphatidic acid (LPA) is a bioactive lipid mediator primarily derived from membrane phospholipids. ...This review provided integrative information and summarized preclinical findings and recent clinical trials of different LPA receptor antagonists in cancer …
Lysophosphatidic acid (LPA) is a bioactive lipid mediator primarily derived from membrane phospholipids. ...This review provid …
Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special?
Balijepalli P, Sitton CC, Meier KE. Balijepalli P, et al. Cells. 2021 Aug 11;10(8):2059. doi: 10.3390/cells10082059. Cells. 2021. PMID: 34440828 Free PMC article. Review.
Lysophosphatidic acid (LPA) refers to a family of simple phospholipids that act as ligands for G protein-coupled receptors. ...Further knowledge of these mechanisms will inform drug discovery, since GPCRs are promising therapeutic targets for cancer....
Lysophosphatidic acid (LPA) refers to a family of simple phospholipids that act as ligands for G protein-coupled receptors. .. …
Autotaxin-Lysophosphatidic Acid: From Inflammation to Cancer Development.
Valdés-Rives SA, González-Arenas A. Valdés-Rives SA, et al. Mediators Inflamm. 2017;2017:9173090. doi: 10.1155/2017/9173090. Epub 2017 Dec 21. Mediators Inflamm. 2017. PMID: 29430083 Free PMC article. Review.
Lysophosphatidic acid (LPA) is a ubiquitous lysophospholipid and one of the main membrane-derived lipid signaling molecules. ...LPA receptors and autotaxin (ATX), a secreted phosphodiesterase that produces this phospholipid, are overexpressed in many cancers …
Lysophosphatidic acid (LPA) is a ubiquitous lysophospholipid and one of the main membrane-derived lipid signaling molecules. . …
The Role of Lysophosphatidic Acid Receptors in Ovarian Cancer: A Minireview.
Cui R, Bai H, Cao G, Zhang Z. Cui R, et al. Crit Rev Eukaryot Gene Expr. 2020;30(3):265-272. doi: 10.1615/CritRevEukaryotGeneExpr.2020031091. Crit Rev Eukaryot Gene Expr. 2020. PMID: 32749113 Review.
Lysophosphatidic acid (LPA) is a bioactive lipid component of ovarian cancer activating factor, which is present at a high concentration in the ascitic fluid and plasma of patients with ovarian cancer. ...LPARs are widely expressed in normal ovary, ben …
Lysophosphatidic acid (LPA) is a bioactive lipid component of ovarian cancer activating factor, which is present at a h …
Exosome-associated lysophosphatidic acid signaling contributes to cancer pain.
Khasabova IA, Khasabov SG, Johns M, Juliette J, Zheng A, Morgan H, Flippen A, Allen K, Golovko MY, Golovko SA, Zhang W, Marti J, Cain D, Seybold VS, Simone DA. Khasabova IA, et al. Pain. 2023 Dec 1;164(12):2684-2695. doi: 10.1097/j.pain.0000000000002967. Epub 2023 Jun 6. Pain. 2023. PMID: 37278638 Free PMC article.
We demonstrated that fibrosarcoma cells express high levels of autotaxin (ATX), the enzyme synthetizing lysophosphatidic acid (LPA). Lysophosphatidic acid increased proliferation of fibrosarcoma cells in vitro. Lysophosphatidic acid is al …
We demonstrated that fibrosarcoma cells express high levels of autotaxin (ATX), the enzyme synthetizing lysophosphatidic acid …
Preclinical detection of lysophosphatidic acid: A new window for ovarian cancer diagnostics.
Huang X, Feng B, Liu M, Liu Z, Li S, Zeng W. Huang X, et al. Talanta. 2022 Sep 1;247:123561. doi: 10.1016/j.talanta.2022.123561. Epub 2022 May 17. Talanta. 2022. PMID: 35609485 Review.
Biomarkers detection for the early diagnosis is crucial to ameliorate the dismal survival rate. Currently, there is much interest in lysophosphatidic acid (LPA), with evidences shown that the elevated LPA level in plasma could serve as an effective biomarker for ova …
Biomarkers detection for the early diagnosis is crucial to ameliorate the dismal survival rate. Currently, there is much interest in lyso …
Lysophosphatidic acid signaling in ovarian cancer.
Jesionowska A, Cecerska-Heryc E, Matoszka N, Dolegowska B. Jesionowska A, et al. J Recept Signal Transduct Res. 2015;35(6):578-84. doi: 10.3109/10799893.2015.1026444. Epub 2015 Sep 22. J Recept Signal Transduct Res. 2015. PMID: 26393967 Review.
Lysophosphatidic acid (LPA) is a bioactive phospholipid that is involved in signal transduction between cells. Plasma and ascites levels of LPA are increased in ovarian cancer patients even in the early stages and thus LPA is considered as a potential diagnos …
Lysophosphatidic acid (LPA) is a bioactive phospholipid that is involved in signal transduction between cells. Plasma and asci …
Lysophosphatidic acid receptors in cancer pathobiology.
Tsujiuchi T, Araki M, Hirane M, Dong Y, Fukushima N. Tsujiuchi T, et al. Histol Histopathol. 2014 Mar;29(3):313-21. doi: 10.14670/HH-29.313. Epub 2013 Nov 6. Histol Histopathol. 2014. PMID: 24194373 Review.
Lysophosphatidic acid (LPA) receptors (LPA1 to LPA6) are G protein-coupled transmembrane and mediate a variety of biological responses through the binding of LPA, such as cell proliferation, migration, morphogenesis and differentiation. ...Moreover, genetic and epig …
Lysophosphatidic acid (LPA) receptors (LPA1 to LPA6) are G protein-coupled transmembrane and mediate a variety of biological r …
Lysophosphatidic Acid: Promoter of Cancer Progression and of Tumor Microenvironment Development. A Promising Target for Anticancer Therapies?
Aiello S, Casiraghi F. Aiello S, et al. Cells. 2021 Jun 4;10(6):1390. doi: 10.3390/cells10061390. Cells. 2021. PMID: 34200030 Free PMC article. Review.
Increased expression of the enzyme autotaxin (ATX) and the consequently increased levels of its product, lysophosphatidic acid (LPA), have been reported in several primary tumors. ...Treatments that counter the TME components, in order to deprive cancer cells …
Increased expression of the enzyme autotaxin (ATX) and the consequently increased levels of its product, lysophosphatidic acid …
1,709 results

Searches related to "lysophosphatidic acid cancer"